Apros Therapeutics

What Apros Therapeutics does

Apros Therapeutics Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2016 and headquartered in San Diego, California. The company is developing tissue-targeted small molecule TLR7 agonists designed to activate innate immunity locally within specific tumors or tissues while minimizing systemic distribution. Its core platform is built on four proprietary chemistry-based approaches: bioconjugation (linking small molecules to proteins for targeted delivery), tissue-targeted chemistry (localizing agonists to specific tissues), conditional activation/deactivation (controlling drug activity under defined conditions), and novel delivery technology (avoiding the need for intratumoral injection).

The company operates three pipeline programs: APR003, an oral GI/liver-targeted TLR7 agonist in Phase 1 clinical trials for advanced colorectal cancer with malignant liver lesions (also applicable to chronic HBV); APR002, an intranasal pan-antiviral TLR7 agonist in discovery; and APR006, an alum-based vaccine adjuvant in discovery. The platform's scientific premise is that localized innate immune activation can convert immunologically "cold" tumors into "hot" tumors — increasing tumor mutational burden and immune cell infiltrate — thereby addressing checkpoint inhibitor non-response in indications such as colorectal cancer with liver metastases and chronic HBV infection.

Apros Therapeutics is pre-revenue and expects to monetize through future drug commercialization, licensing agreements, and partnership collaborations with larger pharmaceutical companies. The company has GMP material available for collaboration and has generated early clinical proof-of-concept with APR003, including observed robust type I interferon responses in advanced colorectal cancer patients. The company operates with a small team (1–10 employees), is founder-led (co-founder Tom Wu), and was funded by an undisclosed Series A financing closed in August 2016; FDA IND clearance for APR003 was received in September 2020, and interim Phase 1 data were presented at SITC 2022.

Name

Apros Therapeutics

Legal name

Apros Therapeutics Inc.

Website

https://aprostx.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Apros Therapeutics is a privately held, clinical-stage biopharmaceutical company developing tissue-targeted small molecule TLR7 agonists for oncology (colorectal cancer with liver metastases) and infectious disease (chronic HBV), with lead program APR003 in Phase 1 trials.

Ownership category

akta.pro rank

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Drug Development and Commercialization: Pre-revenue clinical-stage biopharmaceutical company developing proprietary TLR7 agonists for cancer and infectious disease treatment. Revenue will be generated through drug commercialization, licensing agreements, and potential partnership collaborations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Apros Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of tissue-targeted TLR7 agonist drug candidates for the treatment of cancer and infectious diseases. Its pipeline comprises small-molecule innate-immune agonists designed to locally activate innate immunity at the diseased tissue via a proprietary tissue-targeted chemistry platform, with the lead candidate APR003 in Phase 1 clinical development.

Product overview

Apros Therapeutics is a drug discovery and development company focused on tissue-targeted small molecule innate immune agonists. The company's core technology platform utilizes novel chemistry approaches (including bioconjugation, tissue-targeted chemistry, conditional activation/deactivation, and novel delivery technology) to deliver TLR7 agonists specifically to target tissues for precise dosing. The product portfolio includes three pipeline candidates: APR003 (oral GI/liver-targeted TLR7 agonist for colorectal cancer and HBV in Phase 1), APR002 (intranasal pan-antiviral in discovery), and APR006 (alum vaccine adjuvant in discovery). GMP material is available for collaboration.

Differentiator

Problem solved

Functional benefit

Products and services

• APR003 Lead clinical-stage, tissue-targeted TLR7 agonist drug candidate being developed for oncology; designed to locally activate innate immunity at the tumor site. Currently in Phase 1 clinical development.
• APR002 Discovery-stage, tissue-targeted TLR7 agonist drug candidate being developed for cancer and/or infectious disease indications.
• APR006 Discovery-stage, tissue-targeted TLR7 agonist drug candidate being developed for cancer and/or infectious disease indications.

Quantifiable outcome

• Local activation of TLRs affords effective immune priming with minimal systemic inflammation
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• GMP Material Collaboration PartnerscoreStrategic or Co-development PartnerApros Therapeutics has made GMP (Good Manufacturing Practice) material available for collaboration, indicating active seeking of development and commercialization partners for their TLR7 agonist programs. This suggests partnerships for co-development, manufacturing, or licensing of their proprietary compounds.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Nektar Therapeutics: Clinical-stage biotech with NKTR-262 (a TLR7/8 agonist) combined with NKTR-255 (IL-15) for oncology — a direct competitor in the TLR-agonist oncology space with a similar combination-immunotherapy thesis to Apros's APR003 + checkpoint inhibitor approach.
• Dynavax Technologies: Commercial-stage biotech with HEPLISAV, a TLR9 agonist-adjuvanted HBV vaccine — directly comparable to Apros's HBV program (APR003) and the only TLR-agonist franchise with regulatory approval and commercial revenues.
• Bolt Biotherapeutics: Clinical-stage biotech developing innate immune stimulating antibody conjugates (ISACs) that combine tumor-targeting antibodies with TLR7/8 agonists — directly comparable to Apros's TLR7 + tissue-targeting concept, but using antibody-based rather than small-molecule chemistry.
• Werewolf Therapeutics: Clinical-stage oncology biotech developing INDUKINE molecules designed for conditional activation in the tumor microenvironment — shares Apros's core thesis that localized innate immune activation can widen the therapeutic window of immune agonists.
• Checkmate Pharmaceuticals: Developed CMP-CPS-001, a TLR9 agonist for cancer; acquired by Regeneron in 2022. Closely comparable TLR-agonist oncology developer, validating the broader TLR-agonist commercial opportunity that Apros is pursuing.
• Aceragen (formerly Idera Pharmaceuticals): Acquired Idera's TLR-agonist platform and is developing innate immune-based therapeutics, sharing Apros's TLR agonist focus as a direct modality peer, though targeting different indications (rare diseases).

Broad incumbents

• Johnson & Johnson: Large pharma with Hepcludex (bulevirtide) for HBV and a broad oncology franchise; comparable to Apros in HBV (via APR003) and oncology indications, and a potential strategic acquirer given its history of bolt-on biotech acquisitions.
• Bristol-Myers Squibb: Large pharma with TLR7/8 and broader innate immune oncology programs; potential partner/acquirer for Apros's TLR7 platform and a competing force in TLR-agonist clinical development with significantly greater resources.
• Merck KGaA: Global life sciences company with TLR agonist programs and a broad oncology pipeline; potential partner and competitor for Apros's tissue-targeted TLR7 approach.
• Roche: Developed TLR7 agonist RG7854/RG7795 for HBV and has a major oncology and infectious disease franchise that competes with — and could potentially partner with — Apros in TLR-agonist therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apros Therapeutics